Three-year course of clinical symptomatology in young people at ultra high risk for transition to psychosis

被引:41
作者
Velthorst, E. [1 ]
Nieman, D. H. [1 ]
Klaassen, R. M. C. [1 ]
Becker, H. E. [1 ]
Dingemans, P. M. [1 ]
Linszen, D. H. [1 ]
de Haan, L. [1 ]
机构
[1] Univ Amsterdam, Acad Med Ctr, Dept Psychiat, NL-1105 AZ Amsterdam, Netherlands
关键词
psychotic disorder; symptoms; outcome; recovery; risk factors; CONTROLLED-TRIAL; SCHIZOPHRENIA; PREDICTION; SYMPTOMS; PLACEBO; STATE;
D O I
10.1111/j.1600-0447.2010.01593.x
中图分类号
R749 [精神病学];
学科分类号
100205 ;
摘要
Objective: The investigation into the course of ultra high risk (UHR) symptomatology of those patients who eventually do not meet the psychosis-threshold criteria within the 3-year timeframe of the study. Method: The course of UHR symptoms, GAF score and employment status was investigated in 57 patients who did not make a transition to psychosis and who were examined within the Dutch Prediction of Psychosis Study in Amsterdam, the Netherlands. Results: At the 3- year follow-up, 75% of the patients who did not make a transition to psychosis had remitted from UHR status. With a Generalized Estimation Equation Model it was shown that this group recovered from positive (F = 52.7, P < 0.0001), negative (F = 24.3, P < 0.0001), disorganization (F = 14.4, P < 0.0001) and general symptoms (F = 25.0, P < 0.0001) within the timeframe of the study. In addition, the level of global functioning and likelihood of having a job and/or education significantly improved. The largest improvements occurred within the first year. UHR symptoms did not re-occur after improvement. Conclusion: With the current UHR criteria, a large percentage of the included subjects appear to have transitory complaints and dysfunctioning. A refinement of the UHR criteria may diminish the chance of including 'false positives' in future UHR studies.
引用
收藏
页码:36 / 42
页数:7
相关论文
共 23 条
[1]   Long-Chain ω-3 Fatty Acids for Indicated Prevention of Psychotic Disorders A Randomized, Placebo-Controlled Trial [J].
Amminger, G. Paul ;
Schafer, Miriam R. ;
Papageorgiou, Konstantinos ;
Klier, Claudia M. ;
Cotton, Sue M. ;
Harrigan, Susan M. ;
Mackinnon, Andrew ;
McGorry, Patrick D. ;
Berger, Gregor E. .
ARCHIVES OF GENERAL PSYCHIATRY, 2010, 67 (02) :146-154
[2]  
[Anonymous], 1993, Composite International Diagnostic Interview (CIDI)
[3]  
[Anonymous], 2000, DIAGN STAT MAN MENT, DOI DOI 10.1176/APPI.BOOKS.9780890425787
[4]   The EPSILON study of schizophrenia in five European countries -: Design and methodology for standardising outcome measures and comparing patterns of care and service costs [J].
Becker, T ;
Knapp, M ;
Knudsen, HC ;
Schene, A ;
Tansella, M ;
Thornicroft, G ;
Vázquez-Barquero, JL .
BRITISH JOURNAL OF PSYCHIATRY, 1999, 175 :514-521
[5]   Prediction of psychosis in youth at high clinical risk [J].
Cannon, Tyrone D. ;
Cadenhead, Kristin ;
Cornblatt, Barbara ;
Woods, Scott W. ;
Addington, Jean ;
Walker, Elaine ;
Seidman, Larry J. ;
Perkins, Diana ;
Tsuang, Ming ;
McGlashan, Thomas ;
Heinssen, Robert .
ARCHIVES OF GENERAL PSYCHIATRY, 2008, 65 (01) :28-37
[6]   Early intervention in patients at ultra high risk of psychosis: benefits and risks [J].
de Koning, M. B. ;
Bloemen, O. J. N. ;
van Amelsvoort, T. A. M. J. ;
Becker, H. E. ;
Nieman, D. H. ;
van der Gaag, M. ;
Linszen, D. H. .
ACTA PSYCHIATRICA SCANDINAVICA, 2009, 119 (06) :426-442
[7]  
First M.B., 2001, Structured Clinical Interview for DSM-IV Axis I Disorders
[8]   THE POSITIVE AND NEGATIVE SYNDROME SCALE (PANSS) FOR SCHIZOPHRENIA [J].
KAY, SR ;
FISZBEIN, A ;
OPLER, LA .
SCHIZOPHRENIA BULLETIN, 1987, 13 (02) :261-276
[9]  
Klosterkotter Joachim, 2005, World Psychiatry, V4, P161
[10]   Randomized, double-blind trial of olanzapine versus placebo in patients prodromally symptomatic for psychosis [J].
McGlashan, TH ;
Zipursky, RB ;
Perkins, D ;
Addington, J ;
Miller, T ;
Woods, SW ;
Hawkins, KA ;
Hoffman, RE ;
Preda, A ;
Epstein, I ;
Addington, D ;
Lindborg, S ;
Trzaskoma, Q ;
Tohen, M ;
Breier, A .
AMERICAN JOURNAL OF PSYCHIATRY, 2006, 163 (05) :790-799